Entera Bio Ltd. - (ENTX) closed at $2.77 on October 15, 2026, up 10.8% from the previous close, on volume of 1,442,639 shares (30-day average 518,655).
Data as of October 15, 2026.
Globe Newswire (Tue, 13-Oct 7:00 AM ET)
Globe Newswire (Thu, 8-Oct 8:00 AM ET)
Globe Newswire (Tue, 6-Oct 8:00 AM ET)
Correction: Entera to Participate in Upcoming Fall Investor Conferences
Globe Newswire (Thu, 27-Aug 9:44 AM ET)
Entera to Participate in Upcoming Fall Investor Conferences
Globe Newswire (Thu, 27-Aug 8:00 AM ET)
Globe Newswire (Tue, 18-Aug 8:00 AM ET)
Entera Announces Second Quarter 2026 Financial Results and Business Updates
Globe Newswire (Fri, 7-Aug 4:05 PM ET)
Globe Newswire (Tue, 4-Aug 8:30 AM ET)
Entera Bio to Participate in the Canaccord Genuity 46th Annual Growth Conference
Globe Newswire (Fri, 31-Jul 4:30 PM ET)
Greenberg Traurig Advises Entera Bio in Record $275M Israeli Biotech PIPE
PRNewswire (Wed, 29-Jul 3:00 PM ET)
Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to perform. Its product candidates are: EB613, which is being developed as an oral, osteoanabolic (bone-building) tablet treatment for osteoporosis; EB612, being developed as an oral PTH(1-34) tablet peptide replacement therapy for patients with hypoparathyroidism; EB618, an Oral GLP-1 being developed to tackle obesity; and Oral GLP-2, a peptide tablet alternative for patients suffering from short bowel syndrome. The company operates in Israel.
Entera Bio Ltd. - trades on the NASDAQ stock market under the symbol ENTX.
As of October 16, 2026, ENTX stock price declined to $2.71 with 255,811 million shares trading.
ENTX has a beta of -0.40, meaning it tends to be less sensitive to market movements. ENTX has a correlation of 0.00 to the broad based SPY ETF.
ENTX has a market cap of $469.21 million. This is considered a Small Cap stock.
In the last 3 years, ENTX traded as high as $4.20 and as low as $.52.
ENTX has underperformed the market in the last year with a price return of +13.9% while the SPY ETF gained +15.9%. However, in the short term, ENTX had mixed performance relative to the market. It has outperformed in the last 3 months, returning +52.2% vs +1.4% return in SPY. But in the last 2 weeks, ENTX shares have been beat by the market, returning -6.2% compared to an SPY return of 0.0%.
ENTX support price is $2.62 and resistance is $2.92 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ENTX shares will trade within this expected range on the day.
